Arcutis Biotherapeutics (ARQT) announced that it will present five posters at the 2025 Revolutionizing Atopic Dermatitis, RAD, Conference, which is taking place in Nashville, TN, from June 6-7, 2025. Importantly, the Company will present new data from its INTEGUMENT-OLE study demonstrating the long-term safety and durable efficacy of investigational ZORYVE cream 0.05% in children ages 2 to 5 with AD, consistent with previous studies. Starting at Week 4 of INTEGUMENT-OLE, participants who achieved a validated Investigator Global Assessment (vIGA-AD) score of clear, switched to proactive twice-weekly application. For participants who switched to twice-weekly application, the median duration of disease control was 238 days, consistent with the 281 days observed for adults and children down to age 6 who used twice-weekly dosing.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Buy Rating for Arcutis Biotherapeutics Driven by FDA Approval and Market Potential of Zoryve Foam
- Arcutis Biotherapeutics: Buy Rating Affirmed on FDA Approval and Promising Commercial Prospects for Zoryve Foam
- Arcutis Biotherapeutics: Buy Rating Affirmed on Strong FDA Approvals and Promising Pipeline
- Arcutis Biotherapeutics reports FDA approves sNDA for Zoryve topical foam
- Arcutis announces publication of Genital Psoriasis Wellness Consortium statement
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue